ARTIGOS CIENTÍFICOS PUBLICADOS EM FAVOR DA
FOSFOETANOLAMINA
SODRÉ NETO
Há alegações de diferenças entre fosfoetanolamina produzida no Brasil e calcium EAP , olhando a olho nu vemos duas substancias diferentes , contudo , ainda não tivemos a oportunidade de testar e comparar as substancias num espectrômetro. Já a fosfoetanolamina em associação com fosfocolina temos nos EUA o laboratorio Fisher que comercializa:
https://www.amazon.com/Phosphoethanolamine-Phosphocholine-Phosphatase-Recombinant-Phospho1/dp/B00KCVH1P4
Pequena amostra de artigos científicos já publicados os quais demonstram a eficácia deste remédio tanto em animais como em humanos .
https://www.bv.fapesp.br/pt/bolsas/158097/avaliacao-dos-efeitos-antiproliferativos-e-de-apoptose-da-formulacao-lipossomal-dodac-associado-a-fo/
https://www.bv.fapesp.br/pt/bolsas/113156/alquil-fosfatado-sintetico-precursor-dos-fosfolipidios-de-membrana-celular-com-potencial-efeito-anti/
https://www.bv.fapesp.br/pt/bolsas/144190/estudo-da-citotoxicidade-da-formulacao-lipossomal-dodab-com-o-composto-fosfoetanolamina-sintetica-em/
https://www.bv.fapesp.br/pt/bolsas/154548/avaliacao-antitumoral-da-formulacao-lipossomal-dodac-com-o-composto-fosfoetanolamina-sintetica-em-ce/
https://www.bv.fapesp.br/pt/bolsas/158097/avaliacao-dos-efeitos-antiproliferativos-e-de-apoptose-da-formulacao-lipossomal-dodac-associado-a-fo/
|
Jeon MJ, Lee Y, Ahn S, Lee C, Kim OH, Oh BC, Yu U, Kim H. Acta Radiol. 2015 Sep;56(9):1051-60. doi: 10.1177/0284185114550850. Epub 2014 Sep 30.
2.
IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Esmaeili M, Hamans BC, Navis AC, van Horssen R, Bathen TF, Gribbestad IS, Leenders WP, Heerschap A. Cancer Res. 2014 Sep 1;74(17):4898-907. doi: 10.1158/0008-5472.CAN-14-0008. Epub 2014 Jul 8.
3.
Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects. Ferreira AK, Santana-Lemos BA, Rego EM, Filho OM, Chierice GO, Maria DA. Br J Cancer. 2013 Nov 26;109(11):2819-28. doi: 10.1038/bjc.2013.510. Epub 2013 Nov 7.
4.
Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA. Magn Reson Med. 2014 Jun;71(6):1973-81. doi: 10.1002/mrm.24869. Epub 2013 Jul 22.
5.
Ferreira AK, Meneguelo R, Pereira A, Filho OM, Chierice GO, Maria DA. Biomed Pharmacother. 2013 Jul;67(6):481-7. doi: 10.1016/j.biopha.2013.01.012. Epub 2013 Feb 16.
6.
Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine. Ferreira AK, Freitas VM, Levy D, Ruiz JL, Bydlowski SP, Rici RE, Filho OM, Chierice GO, Maria DA. PLoS One. 2013;8(3):e57937. doi: 10.1371/journal.pone.0057937. Epub 2013 Mar 14.
7.
Ferreira AK, Meneguelo R, Marques FL, Radin A, Filho OM, Neto SC, Chierice GO, Maria DA. Biomed Pharmacother. 2012 Oct;66(7):541-8. doi: 10.1016/j.biopha.2012.04.008. Epub 2012 May 18.
8.
Nanoassisted laser desorption-ionization-MS imaging of tumors. Tata A, Fernandes AM, Santos VG, Alberici RM, Araldi D, Parada CA, Braguini W, Veronez L, Silva Bisson G, Reis FH, Alberici LC, Eberlin MN. Anal Chem. 2012 Aug 7;84(15):6341-5. doi: 10.1021/ac301202q. Epub 2012 Jul 16.
9.
Zhu L, Kate P, Torchilin VP. ACS Nano. 2012 Apr 24;6(4):3491-8. doi: 10.1021/nn300524f. Epub 2012 Mar 14.
10.
Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental study. Ferreira AK, Meneguelo R, Pereira A, Mendonça Filho O, Chierice GO, Maria DA. Anticancer Res. 2012 Jan;32(1):95-104.
11.
Puri BK. Med Hypotheses. 2012 Feb;78(2):312-4. doi: 10.1016/j.mehy.2011.11.010. Epub 2011 Dec 2.
12.
Hydroxypropyl-β-cyclodextrin copolymers and their nanoparticles as doxorubicin delivery system. Wang T, Zhang C, Liang XJ, Liang W, Wu Y. J Pharm Sci. 2011 Mar;100(3):1067-79. doi: 10.1002/jps.22352. Epub 2010 Oct 4.
13.
Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC. PLoS One. 2009 Nov 12;4(11):e7819. doi: 10.1371/journal.pone.0007819.
14.
Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J. Magn Reson Med. 2008 Jul;60(1):33-40. doi: 10.1002/mrm.21647.
15.
Comparison of radiolabeled choline and ethanolamine as probe for cancer detection. Mintz A, Wang L, Ponde DE. Cancer Biol Ther. 2008 May;7(5):742-7. Epub 2008 May 15.
16.
Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F. J Proteome Res. 2007 Jul;6(7):2605-14. Epub 2007 Jun 12.
17.
Role of docosahexaenoic acid in neuronal plasma membranes. Glomset JA. Sci STKE. 2006 Feb 7;2006(321):pe6. Review.
18.
A comparison between in vivo and ex vivo HR-MAS 1H MR spectra of a pediatric posterior fossa lesion. Tugnoli V, Schenetti L, Mucci A, Nocetti L, Toraci C, Mavilla L, Basso G, Rovati R, Tavani F, Zunarelli E, Righi V, Tosi MR. Int J Mol Med. 2005 Aug;16(2):301-7.
19.
Proton-decoupled 31P MRS in untreated pediatric brain tumors. Albers MJ, Krieger MD, Gonzalez-Gomez I, Gilles FH, McComb JG, Nelson MD Jr, Blüml S. Magn Reson Med. 2005 Jan;53(1):22-9.
20.
Arias-Mendoza F, Zakian K, Schwartz A, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR; Cooperative Group on MRS Applications in Cancer. NMR Biomed. 2004 Oct;17(6):382-91. Review.
Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities. Roberts SJ, Stewart AJ, Sadler PJ, Farquharson C. Biochem J. 2004 Aug 15;382(Pt 1):59-65.
22.
Arias-Mendoza F, Smith MR, Brown TR. Acad Radiol. 2004 Apr;11(4):368-76.
23.
Magnetic resonance spectroscopy and clinical cancer prognosis. Zakian KL, Koutcher JA. Acad Radiol. 2004 Apr;11(4):365-7. No abstract available.
24.
Zakian KL, Shukla-Dave A, Meyers P, Gorlick R, Healey J, Thaler HT, Huvos AG, Panicek DM, Koutcher JA. Cancer Res. 2003 Dec 15;63(24):9042-7.
25.
Morvan D, Demidem A, Madelmont JC. Pathol Biol (Paris). 2003 Jul;51(5):256-9.
26.
Franks SE, Smith MR, Arias-Mendoza F, Shaller C, Padavic-Shaller K, Kappler F, Zhang Y, Negendank WG, Brown TR. Leuk Res. 2002 Oct;26(10):919-26.
27.
Flow cytometric determination of lipid peroxidation using fluoresceinated phosphoethanolamine. Maulik G, Salgia R, Makrigiorgos GM. Methods Enzymol. 2002;352:80-91.
28.
Morvan D, Demidem A, Papon J, De Latour M, Madelmont JC. Cancer Res. 2002 Mar 15;62(6):1890-7.
29.
Ziegler A, von Kienlin M, Décorps M, Rémy C. Cancer Res. 2001 Jul 15;61(14):5595-600.
30.
Zeisig R, Müller K, Maurer N, Arndt D, Fahr A. J Membr Biol. 2001 Jul 1;182(1):61-9.
31.
32.
Bhujwalla ZM, Aboagye EO, Gillies RJ, Chacko VP, Mendola CE, Backer JM. Magn Reson Med. 1999 May;41(5):897-903.
33.
Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. Bell JD, Bhakoo KK. NMR Biomed. 1998 Nov;11(7):354-9. Review.
34.
Arndt D, Zeisig R, Eue I, Sternberg B, Fichtner I. Breast Cancer Res Treat. 1997 May;43(3):237-46.
35.
Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Cabot MC, Zhang Z, Cao H, Lavie Y, Giuliano AE, Han TY, Jones RC. Int J Cancer. 1997 Mar 4;70(5):567-74.
36.
Gonen O, Mohebbi A, Stoyanova R, Brown TR. Magn Reson Med. 1997 Feb;37(2):301-6.
37.
Street JC, Alfieri AA, Traganos F, Koutcher JA. Magn Reson Imaging. 1997;15(5):587-96.
38.
Kinoshita Y, Yokota A. NMR Biomed. 1997 Jan;10(1):2-12.
39.
Negendank WG, Padavic-Shaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, Brown TR. Cancer Res. 1995 Aug 1;55(15):3286-94.
40.
Comparison of relative changes in phosphatic metabolites and phospholipids after irradiation. Merchant TE, Alfieri AA, Glonek T, Koutcher JA. Radiat Res. 1995 Apr;142(1):29-38.
Galons JP, Job C, Gillies RJ. Magn Reson Med. 1995 Mar;33(3):422-6.
42.
Phosphorylethanolamine content of human brain tumors. Kinoshita Y, Yokota A, Koga Y. Neurol Med Chir (Tokyo). 1994 Dec;34(12):803-6.
43.
Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4.
44.
In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Gillies RJ, Barry JA, Ross BD. Magn Reson Med. 1994 Sep;32(3):310-8.
45.
Szwergold BS, Kappler F, Moldes M, Shaller C, Brown TR. NMR Biomed. 1994 May;7(3):121-7.
46.
Haidar NE, Andriamampandry C, Carrara M, Kanfer JN, Freysz L, Dreyfus H, Massarelli R. Neurochem Res. 1994 Apr;19(4):457-62.
47.
Adebodun F, Post JF. J Cell Physiol. 1994 Jan;158(1):180-6.
48.
A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, Watanapa P, Iles RA, Urenjak J. Biochim Biophys Acta. 1993 Nov 25;1225(1):71-7.
49.
Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. Smith TA, Bush C, Jameson C, Titley JC, Leach MO, Wilman DE, McCready VR. NMR Biomed. 1993 Sep-Oct;6(5):318-23.
50.
Dixon RM, Tian M. Biochim Biophys Acta. 1993 Apr 30;1181(2):111-21.
51.
Degani H, DeJordy JO, Salomon Y. J Recept Res. 1993;13(1-4):55-68.
52.
Pianet I, Canioni P, Labouesse J, Merle M. Eur J Biochem. 1992 Oct 15;209(2):707-15.
53.
Redmond OM, Bell E, Stack JP, Dervan PA, Carney DN, Hurson B, Ennis JT. Magn Reson Med. 1992 Oct;27(2):226-37.
54.
Merchant TE, Characiejus D, Kasimos JN, Den Otter W, Gierke LW, Glonek T. Magn Reson Med. 1992 Jul;26(1):132-40.
55.
Yushmanov VE, Khristianovich DS, Rozantseva TV, Sibeldina LA. NMR Biomed. 1992 May-Jun;5(3):107-13.
56.
In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies. Cox IJ, Bell JD, Peden CJ, Iles RA, Foster CS, Watanapa P, Williamson RC. NMR Biomed. 1992 May-Jun;5(3):114-20.
57.
Ronen SM, Rushkin E, Degani H. Biochim Biophys Acta. 1992 Mar 20;1138(3):203-12.
58.
Visibility of phospholipids in 31P NMR spectra of human breast tumours in vivo. Lowry M, Porter DA, Twelves CJ, Heasley PE, Smith MA, Richards MA. NMR Biomed. 1992 Jan-Feb;5(1):37-42.
59.
Ronen SM, Rushkin E, Degani H. Biochim Biophys Acta. 1991 Oct 16;1095(1):5-16.
60.
Freyer JP, Schor PL, Jarrett KA, Neeman M, Sillerud LO. Cancer Res. 1991 Aug 1;51(15):3831-7.
Galons JP, Job C, Gillies RJ. Magn Reson Med. 1995 Mar;33(3):422-6.
42.
Phosphorylethanolamine content of human brain tumors. Kinoshita Y, Yokota A, Koga Y. Neurol Med Chir (Tokyo). 1994 Dec;34(12):803-6.
43.
Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4.
44.
In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Gillies RJ, Barry JA, Ross BD. Magn Reson Med. 1994 Sep;32(3):310-8.
45.
Szwergold BS, Kappler F, Moldes M, Shaller C, Brown TR. NMR Biomed. 1994 May;7(3):121-7.
46.
Haidar NE, Andriamampandry C, Carrara M, Kanfer JN, Freysz L, Dreyfus H, Massarelli R. Neurochem Res. 1994 Apr;19(4):457-62.
47.
Adebodun F, Post JF. J Cell Physiol. 1994 Jan;158(1):180-6.
48.
A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, Watanapa P, Iles RA, Urenjak J. Biochim Biophys Acta. 1993 Nov 25;1225(1):71-7.
49.
Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. Smith TA, Bush C, Jameson C, Titley JC, Leach MO, Wilman DE, McCready VR. NMR Biomed. 1993 Sep-Oct;6(5):318-23.
50.
Dixon RM, Tian M. Biochim Biophys Acta. 1993 Apr 30;1181(2):111-21.
51.
Degani H, DeJordy JO, Salomon Y. J Recept Res. 1993;13(1-4):55-68.
52.
Pianet I, Canioni P, Labouesse J, Merle M. Eur J Biochem. 1992 Oct 15;209(2):707-15.
53.
Redmond OM, Bell E, Stack JP, Dervan PA, Carney DN, Hurson B, Ennis JT. Magn Reson Med. 1992 Oct;27(2):226-37.
54.
Merchant TE, Characiejus D, Kasimos JN, Den Otter W, Gierke LW, Glonek T. Magn Reson Med. 1992 Jul;26(1):132-40.
55.
Yushmanov VE, Khristianovich DS, Rozantseva TV, Sibeldina LA. NMR Biomed. 1992 May-Jun;5(3):107-13.
56.
In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies. Cox IJ, Bell JD, Peden CJ, Iles RA, Foster CS, Watanapa P, Williamson RC. NMR Biomed. 1992 May-Jun;5(3):114-20.
57.
Ronen SM, Rushkin E, Degani H. Biochim Biophys Acta. 1992 Mar 20;1138(3):203-12.
58.
Visibility of phospholipids in 31P NMR spectra of human breast tumours in vivo. Lowry M, Porter DA, Twelves CJ, Heasley PE, Smith MA, Richards MA. NMR Biomed. 1992 Jan-Feb;5(1):37-42.
59.
Ronen SM, Rushkin E, Degani H. Biochim Biophys Acta. 1991 Oct 16;1095(1):5-16.
60.
Freyer JP, Schor PL, Jarrett KA, Neeman M, Sillerud LO. Cancer Res. 1991 Aug 1;51(15):3831-7.
31P nuclear magnetic resonance studies of Ehrlich ascites tumor cells. Navon G, Ogawa S, Shulman RG, Yamane T. Proc Natl Acad Sci U S A. 1977 Jan;74(1):87-91.
82.
Phospholipid metabolism in ehrlich ascites tumor cells. II. Turnover rate of ether phospholipids. Waku K, Nakazawa Y, Mori W. J Biochem. 1976 Oct;80(4):711-6.
83.
Wykle RL, Blank ML, Malone B, Snyder F. J Biol Chem. 1972 Sep 10;247(17):5442-7. No abstract available.
84.
Fleshood HL, Pitot HC. Arch Biochem Biophys. 1970 Dec;141(2):423-9. No abstract available.
|